YU49215B - Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja - Google Patents

Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja

Info

Publication number
YU49215B
YU49215B YU51294A YU51294A YU49215B YU 49215 B YU49215 B YU 49215B YU 51294 A YU51294 A YU 51294A YU 51294 A YU51294 A YU 51294A YU 49215 B YU49215 B YU 49215B
Authority
YU
Yugoslavia
Prior art keywords
medicament
treatment
flupirtine
prepare
neurodegenerative diseases
Prior art date
Application number
YU51294A
Other languages
English (en)
Other versions
YU51294A (sh
Inventor
Dr. Michael Schwarz
Dr. Gabriela Pergande
Dr. Jurgen Engel
dr. Bernd Nickel
dr. Heinz Urlich
Dr. Stefan Szelenei
Original Assignee
Viatris Gmbh. & Co.Kg.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viatris Gmbh. & Co.Kg. filed Critical Viatris Gmbh. & Co.Kg.
Publication of YU51294A publication Critical patent/YU51294A/sh
Publication of YU49215B publication Critical patent/YU49215B/sh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Confectionery (AREA)
  • Medicinal Preparation (AREA)

Abstract

Primena aktivnog sastojka flupirtina za dobijanje medikamenta za lečenje cerebralne ishemije. Prljava sadrži još 11 nezavisnih zahteva.
YU51294A 1993-08-17 1994-08-15 Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja YU49215B (sh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4327516A DE4327516A1 (de) 1993-08-17 1993-08-17 Primäre und sekundäre neuroprotektive Wirkung bei neurodegenerativen Erkrankungen von Flupirtin

Publications (2)

Publication Number Publication Date
YU51294A YU51294A (sh) 1998-05-15
YU49215B true YU49215B (sh) 2004-11-25

Family

ID=6495312

Family Applications (1)

Application Number Title Priority Date Filing Date
YU51294A YU49215B (sh) 1993-08-17 1994-08-15 Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja

Country Status (27)

Country Link
US (1) US5721258A (sh)
EP (1) EP0716602B1 (sh)
JP (1) JPH09501664A (sh)
KR (1) KR100341952B1 (sh)
CN (1) CN1086291C (sh)
AT (1) ATE210442T1 (sh)
AU (1) AU694447B2 (sh)
BG (1) BG62430B1 (sh)
BR (1) BR9407293A (sh)
CA (1) CA2169718C (sh)
CZ (1) CZ289040B6 (sh)
DE (2) DE4327516A1 (sh)
DK (1) DK0716602T3 (sh)
EE (1) EE03204B1 (sh)
ES (1) ES2168309T3 (sh)
HR (1) HRP940464A2 (sh)
HU (1) HU227765B1 (sh)
IL (1) IL110681A (sh)
NO (1) NO309842B1 (sh)
NZ (1) NZ273292A (sh)
PT (1) PT716602E (sh)
RU (1) RU2166318C2 (sh)
SK (1) SK283330B6 (sh)
UA (1) UA43351C2 (sh)
WO (1) WO1995005175A1 (sh)
YU (1) YU49215B (sh)
ZA (1) ZA946176B (sh)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19539861A1 (de) * 1995-10-26 1997-04-30 Asta Medica Ag Verwendung von 4-Amino-4-(4-fluorbenzylamino)-1-ethoxy-carbonylaminobenzen zur Prophylaxe und Behandlung der Folgen der akuten und chronischen zerebralen Minderdurchblutung sowie neurodegenerativer Erkrankungen
DE19541405A1 (de) * 1995-11-07 1997-05-15 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen, die mit einer Beeinträchtigung des hämatopoetischen Zellsystems einhergehen
DE19625582A1 (de) * 1996-06-27 1998-01-02 Asta Medica Ag Verwendung von Flupirtin zur Prophylaxe und Therapie von Erkrankungen die mit einer unphysiologisch hohen Zellsterberate einhergehen
EP1034783B1 (en) * 1997-10-27 2004-12-15 Sumitomo Pharmaceuticals Company, Limited Amide derivatives for the treatment of retinal neurodegenerative disorders
WO2001034172A2 (en) * 1999-11-05 2001-05-17 Vela Pharmaceuticals Inc. Methods and compositions for treating reward deficiency syndrome
US6821995B1 (en) 1999-12-01 2004-11-23 Duke University Method of treating batten disease
AU1353901A (en) * 1999-12-01 2001-06-12 Duke University Method of treating batten disease
DE10327674A1 (de) 2003-06-20 2005-01-05 Awd.Pharma Gmbh & Co. Kg Injizierbare Darreichungsform von Flupirtin
DE10328260A1 (de) * 2003-06-23 2005-01-27 Schmidt, K.-G., Dr. med. Flupirtine-Präparat
CA2550023C (en) * 2003-12-16 2011-04-12 Cnsbio Pty Ltd Treatment of neuropathic pain
US20080287399A1 (en) * 2004-12-14 2008-11-20 Astrazeneca Ab Substituted Aminopyridines and Uses Thereof
EP1688141A1 (en) 2005-01-31 2006-08-09 elbion AG The use of flupirtine for the treatment of overactive bladder and associated diseases, and for the treatment of irritable bowel syndrome
US20060258708A1 (en) * 2005-05-16 2006-11-16 Andrulis Peter J Jr Method for treating Parkinson's disease and other neurological diseases
US20080279930A1 (en) * 2007-05-07 2008-11-13 Bernd Terhaag Controlled-Release Flupirtine Compositions, Compacts, Kits and Methods of Making and Use Thereof
DE102011006425A1 (de) 2010-03-31 2011-10-06 Awd.Pharma Gmbh & Co. Kg Pharmazeutische Zubereitung und deren Verwendung
DE102010030053A1 (de) 2010-06-14 2011-12-15 Awd.Pharma Gmbh & Co.Kg Injizierbare Darreichungsform von Flupirtin
MX2016001177A (es) * 2013-07-31 2016-04-29 Teva Pharma Tratamiento de esclerosis multiple con la combinacion de laquinimod y flupirtina.
US11369593B2 (en) * 2017-07-14 2022-06-28 Texas Tech University System Functionalized pyridine carbamates with enhanced neuroprotective activity
DE102017007385A1 (de) 2017-08-02 2019-02-07 Christoph Hoock Maleatfreie feste Arzneimittelformen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4481205A (en) * 1980-09-13 1984-11-06 Degussa Aktiengesellschaft 2-Amino-3-carbethoxyamino-6-(p-fluoro-benzylamino)-pyridine-maleate
DE3337593A1 (de) * 1982-10-27 1984-05-03 Degussa Ag, 6000 Frankfurt 2-amino-3-acylamino-6-benzylamino-pyridin-derivate mit antiepileptischer wirkung
EP0110091B1 (de) * 1982-10-27 1987-01-21 Degussa Aktiengesellschaft 2-Amino-3-Acylamino-6-benzylamino-pyridin-Derivate mit anti-epileptischer Wirkung
NO860825L (no) * 1985-03-23 1986-09-24 Degussa Fremgangsmaate til fremstilling av 2-amino-3-nitro-6-(4-fluor-benzylamino)-pyridin samt 2-amino-3-karbetoksyamino-6-(4-fluor-benzylamino)-pyridin.
IN172468B (sh) * 1990-07-14 1993-08-14 Asta Medica Ag

Also Published As

Publication number Publication date
US5721258A (en) 1998-02-24
CA2169718C (en) 2002-11-12
BG62430B1 (bg) 1999-11-30
SK21496A3 (en) 1997-01-08
SK283330B6 (sk) 2003-06-03
AU7652894A (en) 1995-03-14
DK0716602T3 (da) 2002-03-25
YU51294A (sh) 1998-05-15
HRP940464A2 (en) 1997-06-30
HU227765B1 (en) 2012-02-28
CZ46596A3 (en) 1996-05-15
ZA946176B (en) 1995-03-20
EE03204B1 (et) 1999-08-16
EP0716602A1 (en) 1996-06-19
NO309842B1 (no) 2001-04-09
IL110681A0 (en) 1994-11-11
HUT75650A (en) 1997-05-28
KR100341952B1 (ko) 2003-04-11
NO960607D0 (no) 1996-02-15
AU694447B2 (en) 1998-07-23
DE69429435D1 (de) 2002-01-24
ES2168309T3 (es) 2002-06-16
PT716602E (pt) 2002-05-31
CA2169718A1 (en) 1995-02-23
BR9407293A (pt) 1996-10-01
CZ289040B6 (cs) 2001-10-17
WO1995005175A1 (en) 1995-02-23
BG100356A (bg) 1996-07-31
DE4327516A1 (de) 1995-02-23
NO960607L (no) 1996-02-15
JPH09501664A (ja) 1997-02-18
EP0716602B1 (en) 2001-12-12
KR960703591A (ko) 1996-08-31
IL110681A (en) 1999-08-17
CN1086291C (zh) 2002-06-19
DE69429435T2 (de) 2002-06-13
RU2166318C2 (ru) 2001-05-10
HU9600355D0 (en) 1996-04-29
UA43351C2 (uk) 2001-12-17
ATE210442T1 (de) 2001-12-15
CN1129399A (zh) 1996-08-21
NZ273292A (en) 1999-09-29

Similar Documents

Publication Publication Date Title
YU49215B (sh) Primena flupirtina za dobijanje medikamenta za tretman neurodegenerativnih oboljenja
ES2086270T3 (es) Metabolitos de terfenadina y sus isomeros opticamente puros para tratar trastornos alergicos.
DK0713701T3 (da) 2-Brommelatonin til behandling af søvnforstyrrelser
HRP920667B1 (en) Application of fultripine active substance for preventing muscle deformation
DE69427344T2 (de) Verabreichung von riluzol zur behandlung von neuro-aids
CA2143610A1 (en) Use of norastemizole for the treatment of allergic disorders
DK0412554T3 (da) Sustained-release-præparat til administration i hjernen
TW197423B (sh)
DE69322251T2 (de) Medizinische zusammensetzung
AU4530989A (en) Pharmaceutical composition for the treatment of cerebral edema
ITMI922742A0 (it) Composti ad attivita' terapeutica utili per il trattamento di malattieconnesse ad una carenza di glutatione, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono.
AR059965A2 (es) Uso de 8,9-dehidroestrona para la preparacion de un medicamento antioxidante
DE68905076D1 (de) Pharmazeutische zusammensetzung fuer die behandlung von hautwunden.
ZA944281B (en) Use of efaroxan and its derivatives for the preparation of a medicinal product intented for the treatment of parkinson's disease
CA2135752A1 (en) Use of (E)-2-(p-Fluorophenethyl)-3-Fluoroallylamine in the Treatment of Alzheimer's Disease
NO167381C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktiv (e)-2-(p-fluorfenethyl)-3-fluorallylamin.
FR2691064B3 (fr) Nouveau medicament pour le traitement de l'arythmie.
YU169090A (sh) Tetra hidroimidazo (1,4) benzodiazepini
ITMI911122A0 (it) Composizioni per la terapia topica delle ustioni
SE9203296D0 (sv) The use of inositoltrisphate for the preparing of medicaments
CA2154485A1 (en) Pharmaceutical composition containing 5-morpholinomethyl-3-(4-chlorobenzylideneamine)-2-oxazolidinone and its use for the treatment of cns disorders
AU4246189A (en) Medicament for the treatment of diseases caused by retroviruses
ZA921101B (en) Use of tetra: Hydro-thieno-pyrido-indole derivatives for the prepartion of a medicine for the treatment of skin disorders.
ITMI912238A1 (it) Composti ad attivita' mucolitica e antisettica, procedimento per la loro preparazione e relative composizioni farmaceutiche
UA12937A (uk) Засіб для локальhого лікуваhhя гhійhо-запальhих раh та опіків, іhфіковаhих стафілококом